The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Open accessAbstract
BACKGROUND: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms. METHODS: In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 months. The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P<0.001). A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P=0.008); 10.8% and 13.5%, respectively, died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01). Hospitalizations for heart failure and for any cause were also reduced with eplerenone. A serum potassium level exceeding 5.5 mmol per liter occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P<0.001). CONCLUSIONS: Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This effect was independent of diabetes status, and baseline HbA1c did not modify the effects on the primary outcome.531”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [531]
In the citing paper
“The mortality benefit of spironolactone in the RALES trial and eplerenone in the EMPHASIS-HF trial was consistent in T2DM and non-T2DM patients with HFrEF.158,159”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors Task Force Members, Solal, A. C., Filippatos, G. S., McMurray, J. J. V., Ponikowski, P. P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,535
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationMcMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Self-citationIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationHunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,398
Zannad, F. M., Alla, F., Dousset, B., Pérez, A. J. P., & Pitt, B. (2000) · Circulation · doi:10.1161/01.cir.102.22.2700 · Cited by 946
Self-citationCalculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 653
Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction
Silvestre, J., Heymes, C., Oubénaı̈ssa, A., Robert, V., Aupetit, B., Carayon, A., Bernard Swynghedauw, A., & Delcayre, C. (1999) · Circulation · doi:10.1161/01.cir.99.20.2694 · Cited by 381
Tsutamoto, T., Wada, A., Maeda, K., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Sawaki, M., Fujii, M., Matsumoto, T., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01116-0 · Cited by 367
Hayashi, M., Tsutamoto, T., Wada, A., Tsutsui, T., Ishii, C., Ohno, K., Fujii, M., Taniguchi, A., Hamatani, T., Nozato, Y., et al. (2003) · Circulation · doi:10.1161/01.cir.0000068340.96506.0f · Cited by 319
Iraqi, W., Rossignol, P., Angioı̈, M., Fay, R., Nuée, J., Ketelslegers, J. M., Vincent, J., Pitt, B., & Zannad, F. M. (2009) · Circulation · doi:10.1161/circulationaha.108.809194 · Cited by 274
Self-citationAhmed, A., Zannad, F. M., Love, T. E., Tallaj, J. A., Gheorghiade, M., Ekundayo, O. J., & Pitt, B. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm091 · Cited by 187
Self-citationWhen (Not) to Stop a Clinical Trial for Benefit
Pocock, S. (2005) · JAMA · doi:10.1001/jama.294.17.2228 · Cited by 164
Self-citationMolecular Mechanisms of Myocardial Remodeling. The Role of Aldosterone
Delcayre, C. (2002) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2002.2088 · Cited by 164
Reconsidering the Roles of the Mineralocorticoid Receptor
Funder, J. W. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.119966 · Cited by 149
van Veldhuisen, D. J., Maass, A. H., Priori, S. G., Stolt, P., Gelder, I. C. V., Dickstein, K., & Swedberg, K. B. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp149 · Cited by 132
Self-citationAldosterone and Spironolactone in Heart Failure
Weber, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411009 · Cited by 128
The Clinical Implications of Aldosterone Escape in Congestive Heart Failure
Struthers, A. D. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.04.013 · Cited by 128
Fung, J. W., Yu, C., Yip, G. W., Chan, S. K. W., Yandle, T. G., Richards, M., Nicholls, M. G., & Sanderson, J. E. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00658-1 · Cited by 119
Boccanelli, A., Mureddu, G. F., Cacciatore, G., Clemenza, F., Lenarda, A. D., Gavazzi, A., Porcu, M., Latini, R., Lucci, D., Maggioni, A. P., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn015 · Cited by 117
Aldosterone and cardiac fibrosis: in vitro studies
Fullerton, M., & Funder, J. W. (1994) · Cardiovascular Research · doi:10.1093/cvr/28.12.1863 · Cited by 107
Zannad, F. M., McMurray, J. J. V., Drexler, H., Krum, H., van Veldhuisen, D. J., Swedberg, K. B., Shi, H. H., Vincent, J., & Pitt, B. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq049 · Cited by 87
Self-citationCohn, J. N., Anand, I. S., Latini, R., Masson, S., Chiang, Y., & Glazer, R. D. (2003) · Circulation · doi:10.1161/01.cir.0000091234.45664.62 · Cited by 87
Flagged first, then by citations
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
Self-citation2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Self-citation2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citation2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citation2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation
Metadata
- Authors
- Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B.
- Affiliations
- Inserm (FR)
- Monash University (AU)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- London School of Hygiene & Tropical Medicine (GB)
- University of Michigan (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 11-21
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164705414
- Cited by
- 3,111
- References
- 27
- Citations by year
- 2026: 184 · 2025: 168 · 2024: 167 · 2023: 177 · 2022: 228 · 2021: 197 · 2020: 190 · 2019: 181 · 2018: 178 · 2017: 177 · 2016: 187 · 2015: 227 · 2014: 209 · 2013: 239 · 2012: 216
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, heart failure with reduced ejection fraction, mild symptoms, heart failure hospitalization, cardiovascular mortality, hyperkalemia, ejection fraction
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Cardiovascular Agents, Cardiovascular Diseases, Combined Modality Therapy, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Spironolactone, Proportional Hazards Models, Defibrillators, Implantable, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
